MedTrace Logo

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00257673 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2008-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.

Conditions

Interventions

DRUG

MEM 1003

30 mg twice a day

DRUG

MEM 1003

90 mg MEM 1003 twice a day

DRUG

Placebo for MEM 1003

Placebo twice a day

Sponsors & Collaborators

  • Memory Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Stephen Murray, MD, PhD · Memory Pharmaceutical Corp.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257673 on ClinicalTrials.gov